argenx SE reported $1.58B in Current Liabilities for its fiscal quarter ending in June of 2026.





Current Liabilities Change Date
AstraZeneca USD 31.55B 1.02B Jun/2026
Genmab DKK 1.43B 686M Dec/2025
GlaxoSmithKline GBP 21.53B 895M Jun/2026
GRIFOLS EUR 2.24B 112M Jun/2026
Hikma Pharmaceutical USD 1.45B 603M Dec/2025
Lakefront Biotherapeutics EUR 100.42M 52.44M Mar/2026
Qiagen NV USD 479.11M 33.03M Mar/2026
UCB EUR 4.4B 470M Dec/2025